



2024 Year in Review

As we draw the curtain of 2024, what an adventure year has been: starting from my EMBA studies at Quantic Business School to a memorable trip to China visiting my dear mother. OTI-2024's story has been traveling from Barcelona at European Ophthalmology Forum to Chicago at Academy of Ophthalmology, and from FDA panel reviewers' desk to the virtual meeting room at MDG Boston. The journey of OTI-2024 from a discontinued Phase 3 IOP lowering drug (Trabodenoson) to have become the first curative solution for preventing glaucoma blindness has been eventful, a rather winded road in years of making (since 2015). The rebirth of OTI-2024 and its IPs on securing the drug market exclusivity (after original patents expired) is unprecedented; it represents a new frontier of patent landscape. This breakthrough therapy is a quantum leap in the field of glaucoma, solving the problems (vision loss) which has troubled clinicians and scientists in the past many decades. I am thankful for the steadfast support of OTI's growing team, our investor along with our Taskforce Advisors (Dr Janet Woodcock, Prof John Marshall, Prof Bob Langer, Jon Lourie, JD, Chris Garabedian, Dr Julia Haller, Todd Armstrong, PhD/JD, Ian Catchpole, PhD, Leslie Boyd, PhD, Marie-Louise Jacque, MD, Paul Howes, Gene de Juan Jr. and Flemming Ornskøvd).

We are pioneers and innovators in medicine frontier. Since the first discovery in 2015 of trabecular meshwork rejuvenation through OTI-2024 eye drops, it propels the field re-assessing the benefits of SLT laser for glaucoma (becoming first line choice). The new discovery of pressure sensor raises the risks associated with glaucoma canal surgeries and laser procedures. With OTI-2024 moving from R&D formulation to clinical trials, we are setting the new standards of glaucoma disease management from IOP reduction to IOP normalization (drug holiday); Dr Louis Cantor recently noted at OTI's SAB meeting, "future glaucoma disease management will be largely based on a maintenance therapy by OTI-2024 (drug holiday inducer and stabilizer)". As the inventor of OTI-2024 and MMP platform therapy for glaucoma, I am standing on the shoulders of many giants along with hundreds of million scientists' hard work, e.g. Prof. John Marhsall's 2RT retinal laser on Bruch's membrane rejuvenation, Dr Murray Johnstone's aqueous outflow in pulsatile IOP, Allergan's entire team on Durysta clinical trials, led by Dr Randy Craven, Dr Robert Weinreb and Dr Jason Bacharach, respectively.

The ability of connecting the dots and seeing an invisible link is of creativity in modern times. We are continuing to innovate and pushing the boundaries. As CEO and entrepreneur, I am grateful for the opportunities to learn and grow as OTI-2024 project moves forward attracting venture funds and partnership. Thank you for being a part of OTI's journey. May your Christmas holiday have filled with joys, peace, love, and happiness!

With Sincere Gratitude,

Tina GQ

<https://ophthalmic-innovation.com>